搜索筛选:
搜索耗时5.4058秒,为你在为你在102,285,761篇论文里面共找到 6 篇相符的论文内容
发布年度:
[期刊论文] 作者：MEI Yu-qin,SONG Song-quan,
来源：中国农业科学：英文版 年份：2008
发生在玉米期间的早词法、生理的事件(Zea mays cv。Nongda 108 ) 种子吸收和萌芽被学习。种子的水举起在吸收，然后慢增加的起始的阶段期间随显著增加展出了一个 triphasic 模...
Bone marrow involvement by lymphoma: pathologic investigation from a single center in Northern China
[会议论文] 作者：SHI Yun-fei,LI Xiang-hong,LAI Yu-mei,SONG Yu-qin,SONG Wei-wei,
来源：2015诺贝尔奖获得者医学峰会暨国际肿瘤研究高峰论坛 年份：2015
Objective This study was mainly aimed to retrospectively evaluate the key features of bone marrow (BM) biopsy involvement by lymphoma in Northern China usin...
Bone marrow involvement by lymphoma: pathologic investigation from a single center in Northern China
[会议论文] 作者：SHI Yun-fei,LI Xiang-hong,SONG Yu-qin,SONG Wei-wei,LAI Yu-mei,
来源：2015诺贝尔奖获得者医学峰会暨国际肿瘤研究高峰论坛 年份：2015
Objective This study was mainly aimed to retrospectively evaluate the key features of bone marrow (BM) biopsy involvement by lymphoma in Northern China using bone marrow trephine (BMT) biopsy method....
[期刊论文] 作者：Wei-Ping Liu,Wen Zheng,Yu-Qin Song,Ling-Yan Ping,Gui-Qiang Wang,Jun Zhu,,
来源：World Journal of Gastroenterology 年份：2014
Reactivation of hepatitis B virus(HBV)can occur in lymphoma patients infected with HBV when they receive chemotherapy or immunotherapy.Prophylactic administrati...
Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tis
[期刊论文] 作者：Xiao-Sheng Ding,Lan Mi,Yu-Qin Song,Wei-Ping Liu,Hui Yu,Ning-Jing Lin,Jun Zhu,
来源：世界临床病例杂志 年份：2021
BACKGROUND Academic studies have proved that anti-programmed death-1(PD-1)monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma(cHL).However,most patients ultimately experienced failure or ......
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor t
[期刊论文] 作者：Chang-cheng Sheng,Guang-li Ma,Da Xu,Xiao-qin Liu,Yu-ya Wang,Li Zhang,Chuan-liang Cui,Bing-he Xu,Yu-qin Song,
来源：中国药理学报（英文版） 年份：2021
Camrelizumab,a programmed cell death 1(PD-1)inhibitor,has been approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma,nasopharyngeal cancer and non-small cell lung cancer.The aim of this study was to p......
相关搜索：
